Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > Starpharma’s VivaGel™ Advance to Third Stage

August 2nd, 2004

Starpharma’s VivaGel™ Advance to Third Stage

Abstract:
Starpharma Holdings Limited announced today that VivaGel™, its investigational new drug for the prevention of HIV, is advancing to the next stage of dosing in the current Phase 1 study. VivaGel™ is the first drug product in the world based upon nanoscale structures called dendrimers, to enter human trials.

Source:
Starpharma

Bookmark:

Related News Press

Nanomedicine

UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013

Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013

How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013

MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013